Across TCGA pan-cancer cohorts, SH2B2 mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of SH2B2’s most consistent transcriptional readouts.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where SH2B2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SH2B2 is over-expressed in tumor, although a few such as LUAD show the opposite, repressed pattern.
CCRCC and LUAD are the cancer types where SH2B2 tumor–normal differential expression is most reproducible.